The Role of Active Administration of Peristeen Bowel Evacuation for the Management of Urinary Tract Infection

The Role of Active Administration of Peristeen Bowel Evacuation for the Management of Urinary Tract Infection in Patients With Neurogenic Bladder: a Prospective, Explorative Pilot Study

This study investigates whether active use of transanal irrigation (Peristeen®) effectively manages urinary tract infection among patients with the diagnosis of neurogenic bladder.

This study investigates whether active use of transanal irrigation (Peristeen®) effectively manages urinary tract infection among patients diagnosed with neurogenic bladder. It is a prospective exploratory pilot study, and the participants will be asked to perform transanal irrigation twice weekly for 12 weeks (three months). At each visit, including baseline, the study endpoints will be assessed by basic urinalysis, KUB imaging, Seoul Fecal Scoring, and a survey (Korean Neurogenic Bowel Score).

Inclusion Criteria:

• Between the ages, 5 to 18, and are diagnosed with neurogenic bladder.
• Use CIC (CIC: Clean Intermittent Catheterization) daily to empty the bladder.
• A recent history of fecal incontinence within the last 3 months
• More than two episodes of urinary tract infection and/ or pyuria within the last 6 months

Exclusion Criteria:

• An anatomical abnormality of the bladder neck.

• Known intractable origin of bacteriuria such as urolithiasis (kidney stone) or nonfunctional renal segment.

• Received bladder augmentation surgery

• Patient without completion of toilet training

• Either received following treatment diagnosed according to Peristeen® product safety guideline:

  1. Anorectal malformation
  2. Colorectal cancer
  3. Endoscopic polyp removal surgery in 3 months
  4. Ischemic colitis
  5. Acute inflammatory bowel disease
  6. Acute intestinal diverticulum.
  7. Radiotherapy to the colon
  8. Long-term corticosteroid usage